Costa Ane Francyne, Ribeiro Mariana Goveia Melo, Onofre Alexandre Sherlley Casimiro, de Miranda Onofre Fabiana Botelho
Department of Clinical Analysis, Federal University of Santa Catarina, Florianópolis, Brazil.
Diagn Cytopathol. 2021 Feb;49(2):335-346. doi: 10.1002/dc.24683. Epub 2020 Dec 17.
To systematically review the role of aneuploidy detection alone or in combination with other methods in cervical cancer screening and to evaluate the value of aneuploidy to predict the behavior of premalignant cervical lesions.
We conducted a systematic review based on an electronic search for articles published between 2001 and 2020 across databases including MEDLINE/PubMed, Scopus, and Web of Science. Studies were subjected to data extraction, risk of bias, and narrative synthesis.
A total of 15 articles were included in the review. Eight out of 15 studies (53.3%) were judged to be at a high or unclear risk of bias. From the 15 included studies, the index test to detect aneuploidy was DNA image cytometry (DNA-ICM) in 12 studies and DNA flow cytometry (DNA-FCM) in three studies. Nine studies also evaluated the performance of cytology and/or human papillomavirus (HPV) tests. For DNA-ICM, sensitivity to detect cervical intraepithelial neoplasia or worse (CIN2+) varied between 59.0% and 95.9% and specificity varied between 54.1% and 100%. For DNA-FCM, sensitivity varied between 27.3% to 96.8% and specificity was 100%. For cytological evaluation, sensitivity varied between 25.0% and 70.4% and specificity varied between 70.6% and 99.9%. For HPV detection, sensitivity varied between 39.4% and 100% and specificity varied between 23.3% and 84.3%.
DNA ploidy along with atypical cells findings in cytology and/or HPV detection revealed great value to detect CIN2+ lesions and to predict which lesions are more likely to progress to cervical cancer.
系统评价非整倍体检测单独或与其他方法联合在宫颈癌筛查中的作用,并评估非整倍体对预测宫颈上皮内瘤变行为的价值。
我们基于对2001年至2020年间发表在包括MEDLINE/PubMed、Scopus和Web of Science在内的数据库中的文章进行电子检索,开展了一项系统评价。对研究进行数据提取、偏倚风险评估和叙述性综合分析。
本评价共纳入15篇文章。15项研究中有8项(53.3%)被判定存在高偏倚风险或偏倚风险不明确。在纳入的15项研究中,检测非整倍体的指标检测方法在12项研究中为DNA图像细胞术(DNA-ICM),3项研究中为DNA流式细胞术(DNA-FCM)。9项研究还评估了细胞学和/或人乳头瘤病毒(HPV)检测的性能。对于DNA-ICM,检测宫颈上皮内瘤变或更严重病变(CIN2+)的敏感性在59.0%至95.9%之间,特异性在54.1%至100%之间。对于DNA-FCM,敏感性在27.3%至96.8%之间,特异性为100%。对于细胞学评估,敏感性在25.0%至70.4%之间,特异性在70.6%至99.9%之间。对于HPV检测,敏感性在39.4%至100%之间,特异性在23.3%至84.3%之间。
DNA倍体分析以及细胞学和/或HPV检测中的非典型细胞发现对于检测CIN2+病变以及预测哪些病变更有可能进展为宫颈癌具有重要价值。